<DOC>
	<DOCNO>NCT02182986</DOCNO>
	<brief_summary>Solid organ transplantation important therapeutic option child variety end stage disease . However , immunosuppressive medication require prevent child 's immune system attack reject transplant organ predispose individual develop serious cancer link Epstein-Barr virus ( EBV ) .</brief_summary>
	<brief_title>Biomarkers Post-Transplant Lymphoproliferative Disorders Children</brief_title>
	<detailed_description>EBV-associated post-transplant lymphoproliferative disease ( PTLD ) common malignancy child transplant . Diagnosis effective treatment EBV-associated cancer hamper inability determine child risk develop cancer detect cancer early stage . In study , plan test new `` biomarkers '' blood child tell u early child risk develop EBV-associated cancer cancer present . These study provide new opportunity detection , diagnosis , treatment child EBV-associated , post-transplant cancer .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Subject and/or parent legal guardian must able understand provide informed consent/assent ; Candidate recipient : heart , liver , heart liver , small intestine , liver small intestine , kidney ; Subject enrol within 3 year transplant . Previous diagnosis PTLD ; Transplant recipients lung alone , combination eligible organ type ; Pancreas transplantation exception 'en bloc ' transplant combine liver small intestine multivisceral transplantation ; Any combination list inclusion criterion ; History previous solid organ , stem cell , bone marrow transplantation ; Inability unwillingness legal guardian and/or subject comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Biomarkers</keyword>
	<keyword>Post-Transplant Lymphoproliferative Disorders ( PTLDs )</keyword>
</DOC>